drugset / Trial / NCT05418426
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
RandomizedParallel-groupOpen-labelOther
Summary
An open-label study to assess the PK of estradiol, estrone and progesterone from the DARE-HRT1 intravaginal rings at two different dose strengths.
Timeline
- Start
- 2020-08-18
- Primary completion
- 2021-04-27
- Completion
- 2022-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Estradiol | Other / unclassified | 1 mg | Oral |
| Subject | Progesterone | Other / unclassified | 100 mg | Oral |